We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
-23.86%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$2.34B
AUM Growth
-$463M
(-17%)
Cap. Flow
+$326M
Cap. Flow
% of AUM
13.93%
Top 10 Holdings %
Top 10 Hldgs %
52.09%
Holding
73
New
17
Increased
17
Reduced
10
Closed
27
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Welltower
WELL
|
+$117M |
| 2 |
Encompass Health
EHC
|
+$111M |
| 3 |
AMRN
Amarin Corp
AMRN
|
+$101M |
| 4 |
Haemonetics
HAE
|
+$97.5M |
| 5 |
Bausch Health
BHC
|
+$92.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$140M |
| 2 |
Johnson & Johnson
JNJ
|
+$100M |
| 3 |
HOLX
Hologic
HOLX
|
+$87.5M |
| 4 |
HCA Healthcare
HCA
|
+$65.6M |
| 5 |
XENT
Intersect ENT, Inc
XENT
|
+$63.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.58% |
| 2 | Real Estate | 5.41% |
| 3 | Industrials | 0% |
| 4 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NVRO
1
DELISTED
NEVRO CORP.
NVRO
| $175M | 7.49% |
1,752,620
+582,540
| +50% | +$70.1M |
|
|
2
Haemonetics
HAE
$3.85B
| $143M | 6.13% |
1,438,356
+899,394
| +167% | +$97.5M |
|
3
Aurinia Pharmaceuticals
AUPH
$1.93B
| $142M | 6.06% |
9,763,920
+4,943,590
| +103% | +$87.2M |
|
4
Labcorp
LH
$25.9B
| $136M | 5.83% |
1,256,801
+264,025
| +27% | +$38M |
|
5
Neurocrine Biosciences
NBIX
$18.7B
| $134M | 5.73% |
1,547,740
+740,876
| +92% | +$72.5M |
|
6
Teleflex
TFX
$5.86B
| $119M | 5.09% |
406,930
+97,310
| +31% | +$34M |
|
|
7
Encompass Health
EHC
$11B
| $97.7M | 4.18% |
+1,917,942
| New | +$111M |
|
8
Acadia Pharmaceuticals
ACAD
$4.55B
| $94.2M | 4.03% |
+2,230,474
| New | +$91.9M |
|
9
Madrigal Pharmaceuticals
MDGL
$11.4B
| $93.6M | 4% |
1,402,250
+313,940
| +29% | +$26.2M |
|
10
Zimmer Biomet
ZBH
$18.4B
| $83.3M | 3.56% |
848,947
+388,525
| +84% | +$50.9M |
|
|
BPMC
11
DELISTED
Blueprint Medicines
BPMC
| $74.9M | 3.2% |
1,280,370
+971,832
| +315% | +$62.5M |
|
12
Charles River Laboratories
CRL
$11.3B
| $73.8M | 3.15% |
584,620
+409,620
| +234% | +$61.4M |
|
13
CVS Health
CVS
$134B
| $73.2M | 3.13% |
+1,234,120
| New | +$82.4M |
|
|
14
Welltower
WELL
$170B
| $72.4M | 3.1% |
+1,582,360
| New | +$117M |
|
15
Humana
HUM
$44B
| $64M | 2.74% |
203,870
+47,440
| +30% | +$16M |
|
|
16
Bausch Health
BHC
$2.25B
| $59.2M | 2.53% |
+3,819,630
| New | +$92.1M |
|
17
LivaNova
LIVN
$4.45B
| $55.5M | 2.37% |
+1,225,890
| New | +$79.4M |
|
18
Omega Healthcare
OHI
$15B
| $54.1M | 2.31% |
+2,038,390
| New | +$77.3M |
|
19
IQVIA
IQV
$39.1B
| $51.6M | 2.21% |
478,580
+194,050
| +68% | +$27.7M |
|
20
UnitedHealth
UNH
$383B
| $42.6M | 1.82% |
170,830
-127,890
| -43% | -$35.2M |
|
21
CONMED
CNMD
$1.41B
| $39.4M | 1.68% |
687,466
+151,446
| +28% | +$14M |
|
22
AbbVie
ABBV
$455B
| $35.3M | 1.51% |
+463,900
| New | +$39.5M |
|
23
Pediatrix Medical
MD
$2.17B
| $30.8M | 1.32% |
2,646,200
+1,571,720
| +146% | +$32.4M |
|
|
AMRN
24
Amarin Corp
AMRN
$298M
| $30.5M | 1.31% |
381,858
+303,804
| +389% | +$101M |
|
25
Medtronic
MDT
$110B
| $30.1M | 1.28% |
333,330
-514,370
| -61% | -$54.7M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q1 2020 Portfolio in Review
As of Q1 2020, HealthCor Management held 73 positions worth $2.34B, down 17% from $2.8B the previous quarter. Its ten largest holdings account for 52% of the portfolio.
HealthCor Management deployed $326M of net new capital in Q1 2020, opening 17 new positions and adding to 17 existing holdings. Its largest new stake was Welltower: 1,582,360 shares worth $72.4M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier, followed by Real Estate and Industrials.
On the sell side, the largest reduction was Hologic, an estimated $87.5M trimmed.
- HealthCor Management's largest Q1 2020 buy was Welltower: 1,582,360 shares worth $72.4M.
- HealthCor Management added most to Amarin Corp in Q1 2020, an estimated $101M increase.
- HealthCor Management's biggest Q1 2020 reduction was Hologic, cutting an estimated $87.5M.
- HealthCor Management fully exited Regeneron Pharmaceuticals in Q1 2020, selling an estimated $140M.
- HealthCor Management's ten largest holdings make up 52% of its $2.34B portfolio in Q1 2020.
- HealthCor Management opened 17 new positions and closed 27 in Q1 2020.
- HealthCor Management's portfolio value fell 17% quarter-over-quarter to $2.34B.
Based on HealthCor Management's 13F filing for Q1 2020, filed 15 May 2020.